摘要
目的 探讨注射依奇珠单抗和司库奇尤单抗治疗重度寻常型银屑病的临床效果,为临床医师合理选用药物以及控制病情发展、降低疾病复发提供实践依据。方法 选择2020年1月-2023年7月北京市大兴区人民医院皮肤科重度斑块型银屑病患者100例。按照随机数字表法分为司库奇尤组和依奇珠组(每组50例)。对比治疗前及治疗后两组生活质量指数(DLQI)与皮损严重程度评分(PASI)、外周血C反应蛋白(CRP)、类风湿因子(RF)、白细胞介素-2(IL-2)、白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)表达及皮肤屏障功能,并分析两组药物疗效及安全性。结果 两组治疗效果无统计学差异(P>0.05)。两组治疗后DLQI及PASI评分均低于治疗前,且司库奇尤组PASI评分低于依奇珠组,差异有统计学意义(P<0.05);两组患者DLQI评分比较无统计学差异(P>0.05);两组治疗后CRP、类风湿因子、IL-2、IL-17以及TNF-α水平均降低,且司库奇尤组患者的CRP、类风湿因子、IL-2以及TNF-α水平低于依奇珠组,差异有统计学意义(P<0.05);两组IL-17比较无统计学差异(P>0.05)。两组治疗后患者皮脂含量和角质层含水量均升高,差异有统计学意义(P<0.05);司库奇尤组患者的皮质含量、角质层含水量及测量差高于依奇珠组,差异有统计学意义(P<0.05);依奇珠组不良反应总发生率低于司库奇尤组,差异有统计学意义(P<0.05)。结论 依奇珠单抗和司库奇尤单抗治疗重度寻常型银屑病疗效确切,司库奇尤单抗治疗皮肤改善更佳,免疫因子水平降低更迅速,功效更持久,而依奇珠单抗治疗副作用较小。
Objective To investigate the clinical effect of injection of ixekizumab and secukinumab in the treatment of severe psoriasis vulgaris,and to provide practical basis for clinicians to rationally select drugs,control the development of the disease and reduce the recurrence of the disease.Methods From January 2020 to July 2023,100 patients with severe plaque psoriasis in the Department of Dermatology,Beijing Daxing District People's Hospital were selected.According to the random number table method,they were divided into secukinumab group and ixekizumab group(50 patients in each group).The quality of life index(DLQI)and skin lesion severity score(PASI),peripheral blood C-reactive protein(CRP),rheumatoid factor(RF),interleukin-2(IL-2),interleukin-17(IL-17),tumor necrosis factor-α(TNF-α)expression and skin barrier function were compared between the two groups before and after treatment,and the efficacy and safety of the two groups were analyzed.Results There was no significant difference in the therapeutic effect between the two groups(P>0.05).After treatment,the DLQI and PASI scores of the two groups were lower than those before treatment,and the PASI score of the secukinumab group was lower than that of the ixekizumab group,the difference was statistically significant(P<0.05),while there was no significant difference in DLQI score between the two groups(P>0.05).After treatment,the levels of CRP,rheumatoid factor,IL-2,IL-17 and TNF-αin the two groups decreased,and the levels of CRP,rheumatoid factor,IL-2 and TNF-αin the secukinumab group were lower than those in the ixekizumab group,the differences were statistically significant(P<0.05),while there was no significant difference in IL-17 between the two groups(P>0.05).After treatment,the sebum content and stratum corneum water content of the two groups increased,and the difference was statistically significant(P<0.05).The cortical content,stratum corneum water content and measurement difference of the patients in the secukinumab group were higher than those in the ixekizumab group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the ixekizumab group was lower than that in the secukinumab group,and the difference was statistically significant(P<0.05).Conclusion Ixekizumab and secukinumab are effective in the treatment of severe psoriasis vulgaris.While,secukinumab has better skin improvement,faster reduction of immune factor levels,and longer efficacy in the treatment of severe psoriasis vulgaris,but ixekizumab has fewer side effects.
作者
杨勖彤
孙晓岩
YANG Xutong;SUN Xiaoyan(Department of Dermatology,Beijing Daxing District People's Hospital,Beijing 102600,China)
出处
《医学信息》
2025年第17期98-102,共5页
Journal of Medical Information
基金
中央级公益性科研院所基本科研业务费专项资金(编号:ZZ17-XRZ-0671)。
作者简介
杨勖彤(1995.2-),女,北京人,硕士,主治医师,主要从事银屑病诊疗研究;通讯作者:孙晓岩(1978.7-),女,山东青岛人,硕士,副主任医师,主要从事银屑病及代谢相关、脱发、特应性皮炎诊疗研究。
